Description
1-Linoleoyl-2-hydroxy-sn-glycero-3-PA (sodium salt) (1-linoleoyl LPA) is an agonist of the LPA2 receptor and a glycerophospholipid containing linoleic acid (Item Nos. 90150 | 90150.1 | 21909) at the sn-1 position.1 It is the most abundant LPA in mouse and human plasma.2,3 1-Linoleoyl LPA selectively increases intracellular calcium levels in LPA2 receptor-expressing Sf9 cells (EC50 = ~10 nM) over LPA1 and LPA3 receptor-expressing Sf9 cells (EC50s = ~200 and ~80 nM, respectively).1 Serum levels of 1-linoleoyl LPA are increased in mice bearing NCTC clone 2472 tumors.4 Plasma 1-linoleoyl LPA levels are decreased in patients with primary progressive, but not relapsing-remitting, multiple sclerosis and are negatively correlated with neurological deficit severity.5WARNING This product is not for human or veterinary use.
References
[1] KOJI BANDOH . Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species[J]. FEBS Letters, 2000, 478 1: Pages 159-165. DOI:
10.1016/s0014-5793(00)01827-5[2] DANIEL L. BAKER . Direct Quantitative Analysis of Lysophosphatidic Acid Molecular Species by Stable Isotope Dilution Electrospray Ionization Liquid Chromatography–Mass Spectrometry[J]. Analytical biochemistry, 2001, 292 2: Pages 287-295. DOI:
10.1006/abio.2001.5063[3] KUNIYUKI KANO. Suppressing postcollection lysophosphatidic acid metabolism improves the precision of plasma LPA quantification.[J]. ACS Applied Materials & Interfaces, 2021: 100029. DOI:
10.1016/j.jlr.2021.100029[4] IRYNA A KHASABOVA. Exosome-associated lysophosphatidic acid signaling contributes to cancer pain.[J]. PAIN®, 2023: 2684-2695. DOI:
10.1097/j.pain.0000000000002967[5] MARIO AMATRUDA. Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration.[J]. Scientific Reports, 2020: 15644. DOI:
10.1038/s41598-020-72654-8
